Centivax
Centivax's mission is to accelerate the world’s transition to a post-pathogen humanity. The company is focused on developing broad-spectrum vaccines and broad-spectrum anti-infectives to prevent and combat rapidly mutating viruses and multidrug-resistant bacteria. Their innovative technologies include epitope-focusing and computational immuno-engineering, supported by significant partnerships and recognitions such as the Gates Foundation Grand Challenge. They are actively engaged in pre-clinical development, clinical readiness, and strategic collaborations to make pandemics obsolete and improve global health security.
Industries
Nr. of Employees
small (1-50)
Centivax
Patents
Products
Universal (broad-spectrum) influenza vaccine (preclinical)
A vaccine program designed to generate immunity against conserved influenza epitopes; completed preclinical studies in multiple animal species and human immune organoids, with plans for clinical testing.
Broad-spectrum antibody therapeutics (programs)
Pipeline of broadly neutralizing antibody programs including anti-infectives, anti-wound pathogen antibodies, and antivenom antibody programs derived from human repertoires.
Broad-spectrum injectable for COVID-19 (clinical development partnership)
A broad-spectrum antibody injectable program for SARS-CoV-2 advanced into strategic partnerships to initiate clinical development with external research centers and funding support.
Centivax flu vaccine
A broad-spectrum influenza vaccine developed using patented epitope-focusing technology to target conserved, non-mutating parts of pathogens.
Universal Snake Antivenom
Developing antibody therapies to broadly neutralize the toxins in snake venom to prevent snakebite mortality and morbidity, from all snake species worldwide.
Broad-Spectrum Anti-Infectives
Developing universal vaccines and broad-spectrum antibody programs targeting multidrug-resistant bacteria, supported by military and medical research consortia.
Universal (broad-spectrum) influenza vaccine (preclinical)
A vaccine program designed to generate immunity against conserved influenza epitopes; completed preclinical studies in multiple animal species and human immune organoids, with plans for clinical testing.
Broad-spectrum antibody therapeutics (programs)
Pipeline of broadly neutralizing antibody programs including anti-infectives, anti-wound pathogen antibodies, and antivenom antibody programs derived from human repertoires.
Broad-spectrum injectable for COVID-19 (clinical development partnership)
A broad-spectrum antibody injectable program for SARS-CoV-2 advanced into strategic partnerships to initiate clinical development with external research centers and funding support.
Centivax flu vaccine
A broad-spectrum influenza vaccine developed using patented epitope-focusing technology to target conserved, non-mutating parts of pathogens.
Universal Snake Antivenom
Developing antibody therapies to broadly neutralize the toxins in snake venom to prevent snakebite mortality and morbidity, from all snake species worldwide.
Broad-Spectrum Anti-Infectives
Developing universal vaccines and broad-spectrum antibody programs targeting multidrug-resistant bacteria, supported by military and medical research consortia.
Services
Collaborative development programs, CRADAs and sponsored research with government laboratories and non-profit funders to support preclinical and clinical development.
Collaborative development programs, CRADAs and sponsored research with government laboratories and non-profit funders to support preclinical and clinical development.
Expertise Areas
- Broad-spectrum vaccine development
- Antibody discovery and engineering
- Computational immunology and machine learning
- Preclinical animal models and in vivo evaluation
Key Technologies
- Epitope-focused immunogen design
- Next-generation sequencing (immune repertoire sequencing)
- Single-cell receptor sequencing
- Machine learning for antibody engineering
News & Updates
CEPI reports on innovative vaccine technology that could enable universal vaccines for fast-mutating viruses.
Partnership aimed at advancing universal vaccine development and clinical testing.
Discussion on the importance of broad-spectrum influenza vaccines supported by Centivax's technology.
Collaboration to develop strategies and vaccines to combat influenza.
Monitoring and response to emerging avian influenza strains.
Interview discussing innovative approaches to vaccine development and pandemic preparedness.
CEPI reports on innovative vaccine technology that could enable universal vaccines for fast-mutating viruses.
Partnership aimed at advancing universal vaccine development and clinical testing.
Discussion on the importance of broad-spectrum influenza vaccines supported by Centivax's technology.
Collaboration to develop strategies and vaccines to combat influenza.
Monitoring and response to emerging avian influenza strains.
Interview discussing innovative approaches to vaccine development and pandemic preparedness.